Injectable Platelet-Rich FibrinNCT07787949
Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Grade II Furcation Defects
A study testing Minimally invasive non-surgical technique (MINST) and Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection in people with Injectable Platelet-Rich Fibrin and Minimally Invasive, run by October 6 University at 1 site in Egypt.
Trial summary
This study aims to compare the clinical and radiographic effectiveness of injectable platelet-rich fibrin (i-PRF) combined with minimally invasive non-surgical therapy (MINST) versus MINST alone in the management of class II furcation defects. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Injectable Platelet-Rich Fibrin, Minimally Invasive, Non-Surgical Technique
- What is being tested?
- Minimally invasive non-surgical technique (MINST) and Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteEgypt
- Study dates
- 11 Mar 2026to 11 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients of both genders >18 years old, medically free of systemic diseases affecting periodontal regeneration.
- Diagnosis of stage III, grade B periodontitis (according to the AAP/EFP classification 2018) with the presence of class II furcation defect in either the maxillary (buccal) or mandibular arch (buccal or lingual) as determined by clinical evaluation and confirmed by radiographic evaluation.
- Gingival margin and interdental bone positioned coronally to the furcation entrance.
- Commitment to maintenance visits and follow-up.
- Absence of primary endodontic lesions.
Who cannot join
- Patients suffering from any systemic diseases that may affect the outcome of periodontal therapy, including diabetes, immune deficiencies, etc;
- Patients that received periodontal surgical treatments in the past 12 months.
- Smoking (current or in past 5 years)
- Prolonged treatment with antibiotics or anti-inflammatory agents within 6 months prior to periodontal therapy.
- Pregnant and lactating females.
- Teeth with hopeless prognosis
- Third molars
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
October 6 University (Faculty of Dentistry)
Giza, Giza Governorate, 12511
Moustafa A Ahmed, B.D.S, 00201098378998, 23110295.pg@o6u.edu.eg
Reham L Aggour, MD
About this study
Official title: Evaluation of Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Grade II Furcation Defects: A Randomized Clinical Trial
This study aims to compare the clinical and radiographic effectiveness of injectable platelet-rich fibrin (i-PRF) combined with minimally invasive non-surgical therapy (MINST) versus MINST alone in the management of class II furcation defects.
Read the detailed description
Periodontitis is a multifactorial inflammatory disease that occurs due to the challenge between the host response and specific periodontal pathogens, leading to a gradual destruction of the periodontal supporting tissues over time.
Different regenerative approaches have been proposed including guided tissue regeneration (GTR); bone grafts, bioactive agents such as enamel matrix derivative (EMD) and platelet concentrates.
Using the minimally invasive nonsurgical technique (MINST) implements magnification with microscope/loupes and delicate instruments, to perform the periodontal debridement with more effective root debridement and less soft tissue trauma. MINST significantly improve the visualization and root decontamination, and at the same time preserve the gingival margin and consequently improve the aesthetic results and tissue stability.
- Conditions
- Injectable Platelet-Rich Fibrin, Minimally Invasive, Non-Surgical Technique, Grade II Furcation Defects
- Being tested
- Minimally invasive non-surgical technique (MINST), Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Minimally invasive non-surgical technique (MINST)Procedure or surgery
Patients will receive minimally invasive non-surgical technique (MINST) alone
Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injectionProcedure or surgery
Patients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection
| Study group | Role | What they receive |
|---|---|---|
| Positive control group | Active comparator | Patients will receive minimally invasive non-surgical technique (MINST) alone Receives: Procedure: Minimally invasive non-surgical technique (MINST) |
| Test group | Experimental | Patients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection Receives: Procedure: Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Radiographic Bone Fill at the Furcation Site
Radiographic bone fill at the furcation site will be assessed using cone-beam computed tomography (CBCT). The analysis will include measurement of the filled bone volume (FBV) at the furcation area using segmentation.
Measured: 6 months after treatment
Secondary outcomes (6)
Change in Horizontal Clinical Attachment Level
Horizontal clinical attachment level will be assessed using periodontal probing at baseline and 6 months after treatment.
Measured: 6 months after treatment
Change in Vertical Clinical Attachment Level
Vertical clinical attachment levels will be assessed using periodontal probing at baseline and 6 months after treatment.
Measured: 6 months after treatment
Change in Probing Pocket Depth
Probing pocket depth (PPD) will be measured in millimeters from the gingival margin to the base of the periodontal sulcus at six sites per tooth using a UNC-15 periodontal probe. Measurements will be recorded at baseline and 6 months after treatment.
Measured: 6 months after treatment
Change in Gingival Margin Location
The location of the gingival margin will be assessed by measuring the distance from the cemento-enamel junction (CEJ) to the gingival margin. Measurements will be recorded at baseline and 6 months after treatment.
Measured: 6 months after treatment
Change in Plaque Index
Plaque index (PI) will be assessed to evaluate oral hygiene status by measuring dental plaque accumulation in areas adjacent to the gingival margin. Plaque index will be recorded at baseline and 6 months after treatment.
Measured: 6 months after treatment
Change in Bleeding on Probing
Bleeding on probing (BoP) will be assessed by gently inserting a periodontal probe into the gingival sulcus at the base of the interdental papilla and recording the intensity of bleeding after a short delay. BoP will be assessed at baseline and 6 months after treatment.
Measured: 6 months after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2026
- Study start11 Mar 2026
- Primary completion11 Mar 2027 (estimated)
- Study completion11 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Injectable Platelet-Rich FibrinStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- October 6 University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Moustafa Awadallah Elaref Ahmed, October 6 University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07787949
- Sponsor's protocol ID
- 23110295
- Status last verified
- Aug 2026
- First submitted
- 23 Aug 2026
- Last updated
- 26 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Grade II Furcation Defects: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07787949
- Acronym / sponsor ID
- 23110295
- Conditions
- Injectable Platelet-Rich Fibrin, Minimally Invasive, Non-Surgical Technique, Grade II Furcation Defects
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- October 6 UniversityUniversity, hospital or other
- Study start
- 11 Mar 2026 (actual)
- Primary completion
- 11 Mar 2027 (estimated)
- Study completion
- 11 Mar 2027 (estimated)
- First posted
- 26 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the clinical and radiographic effectiveness of injectable platelet-rich fibrin (i-PRF) combined with minimally invasive non-surgical therapy (MINST) versus MINST alone in the management of class II furcation defects.
Detailed description
Periodontitis is a multifactorial inflammatory disease that occurs due to the challenge between the host response and specific periodontal pathogens, leading to a gradual destruction of the periodontal supporting tissues over time.
Different regenerative approaches have been proposed including guided tissue regeneration (GTR); bone grafts, bioactive agents such as enamel matrix derivative (EMD) and platelet concentrates.
Using the minimally invasive nonsurgical technique (MINST) implements magnification with microscope/loupes and delicate instruments, to perform the periodontal debridement with more effective root debridement and less soft tissue trauma. MINST significantly improve the visualization and root decontamination, and at the same time preserve the gingival margin and consequently improve the aesthetic results and tissue stability.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Positive control group | Active comparator | Procedure: Minimally invasive non-surgical technique (MINST)Patients will receive minimally invasive non-surgical technique (MINST) alone |
| Test group | Experimental | Procedure: Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injectionPatients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients of both genders >18 years old, medically free of systemic diseases affecting periodontal regeneration.
- Diagnosis of stage III, grade B periodontitis (according to the AAP/EFP classification 2018) with the presence of class II furcation defect in either the maxillary (buccal) or mandibular arch (buccal or lingual) as determined by clinical evaluation and confirmed by radiographic evaluation.
- Gingival margin and interdental bone positioned coronally to the furcation entrance.
- Commitment to maintenance visits and follow-up.
- Absence of primary endodontic lesions.
Key exclusion criteria (7 listed)
- Patients suffering from any systemic diseases that may affect the outcome of periodontal therapy, including diabetes, immune deficiencies, etc;
- Patients that received periodontal surgical treatments in the past 12 months.
- Smoking (current or in past 5 years)
- Prolonged treatment with antibiotics or anti-inflammatory agents within 6 months prior to periodontal therapy.
- Pregnant and lactating females.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Minimally invasive non-surgical technique (MINST)Patients will receive minimally invasive non-surgical technique (MINST) alone | Procedure or surgery | Positive control group |
| Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injectionPatients will receive minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection | Procedure or surgery | Test group |
Primary outcome
Change in Radiographic Bone Fill at the Furcation Site
Time frame: 6 months after treatment
Radiographic bone fill at the furcation site will be assessed using cone-beam computed tomography (CBCT). The analysis will include measurement of the filled bone volume (FBV) at the furcation area using segmentation.
6 secondary outcomes
Change in Horizontal Clinical Attachment Level
Time frame: 6 months after treatment
Change in Vertical Clinical Attachment Level
Time frame: 6 months after treatment
Change in Probing Pocket Depth
Time frame: 6 months after treatment
Change in Gingival Margin Location
Time frame: 6 months after treatment
Change in Plaque Index
Time frame: 6 months after treatment
Change in Bleeding on Probing
Time frame: 6 months after treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Injectable Platelet-Rich Fibrin
Not yet recruiting
Effect of Ascorbic Acid-Loaded I-PRF With Partially Demineralized Dentin Graft on Alveolar Ridge Preservation
Alveolar Ridge Preservation Post-Extraction Bone Healing Dental Implant Site Development Tooth Loss, Alveolar Bone Regeneration Following Odontectomy
Not yet recruiting
Microneedling-Assisted i-PRF for Interdental Papilla Deficiency
Interdental Papilla Deficiency
Not yet recruiting
Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis.
Chronic Apical Periodontitis, Pulp Necrosis
RecruitingPhase 3
Treatment of Class II Mandibular Furcation Defects
Class II Furcation Defect
Not yet recruiting
Injectable Platelet-Rich Fibrin and Microneedling With or Without Vitamin C for Gingival Phenotype Augmentation.
Thin Gingival Phenotype
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Minimally invasive non-surgical technique (MINST) and Minimally invasive non-surgical technique (MINST) + injectable platelet-rich fibrin (i-PRF) injection in people with Injectable Platelet-Rich Fibrin and Minimally Invasive, run by October 6 University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Moustafa A Ahmed, B.D.S (00201098378998, 23110295.pg@o6u.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Radiographic Bone Fill at the Furcation Site (time frame: 6 months after treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.